Market Overview:

The global generic injectables market reached a value of US$ 40.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 65.4 Billion by 2027, exhibiting at a CAGR of 8.6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

A generic injectable is a drug formulated with the same active pharmaceutical ingredient as its branded counterpart in strength, dosage form, safety, performance, quality, intended use, side effects, and route of administration. It is as safe and effective as the innovator drug and is consequently used for administering the medication rapidly into the body. It facilitates the easy absorption of medicines in liquid form, which helps reduce the frequency of dosage administration without affecting the efficacy of the treatment. Besides this, it is cost-effective and does not require investment in testing, promotional activities, and research and development (R&D) compared to its branded counterparts. As a result, generic injectables are extensively utilized in treating cancer, diabetes, osteoporosis, osteoarthritis, rheumatoid arthritis, and respiratory, neurological, and cardiovascular disorders.

Generic Injectables Market Trends:

The growing global geriatric population, which is more susceptible to several chronic medical ailments, such as diabetes, cancer, and cardiovascular diseases, represents one of the key factors driving the demand for generic injectables worldwide. In addition, the rising occurrence of lifestyle disorders due to hectic schedules, changing dietary patterns, and sedentary lifestyles of individuals are positively influencing the market. Apart from this, initiatives undertaken by governing authorities of numerous countries to support key manufacturers and sellers are offering lucrative growth opportunities to manufacturers. This, along with the widespread adoption of advanced technologies in the manufacturing process of generic injectables, is propelling the market growth. Furthermore, the expansion of offline pharmacies, along with the easy availability of generic injectables via online pharmacies, is offering a favorable market outlook. The emerging trend of online shopping offers consumers a wide range of products, free doorstep delivery, exciting deals and discounts, and secured payment methods is anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global generic injectables market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on therapeutic area, container, and distribution channel.

Breakup by Therapeutic Area:

• Oncology
• Anaesthesia
• Anti-infectives
• Parenteral Nutrition
• Cardiovascular
   

The oncology segment currently dominates the market due to the increasing number of cancer patients.

Breakup by Container:

• Vials
• Ampoules
• Premix
• Prefilled Syringes
   

On the basis of the container, the market has been segmented into vials, ampoules, premix, and prefilled syringes.

Breakup by Distribution Channel:

• Hospitals
• Retail Pharmacy 
   

Hospitals hold the largest market share due to the increasing cases of chronic medical disorders and the growing expansion of hospitals across the globe.

Regional Insights:

• Europe
• North America
• Asia 
• Latin America
• Middle East and Africa
   

North America enjoys the leading position in the market due to the existence of various leading manufacturers in the country.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being

• Hospira (Pfizer)
• Fresenius Kabi
• Hikma
• Sandoz (Novartis)
• Sagent
• Sanofi
• Baxter
   

This report provides a deep insight into the global generic injectables industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.

Report Coverage: